Other factors associated with modest benefit included high blood pressure and low antiplatelet usage. “All three of these factors do not apply to the typical stroke-prone patient seen in the U.S. clinic,” commented James Meschia, MD , chair of neurology at the Mayo Clinic in Jacksonville, Fla. He also cautioned about some surprising findings: How much B vitamin was given, baseline homocysteine levels, and how much homocysteine subsequently dropped didn’t seem to have an impact on stroke. That was unexpected, given that the proposed mechanism of stroke reduction is homocysteine lowering. “Until we can understand why these particular subgroups do not seem to matter, it does call into question how compelling the finding is that B vitamin supplementation lowers stroke risk,” Meschia said. Regardless, a 7% relative reduction of patients’ typically 1% to 2% annual stroke risk probably wouldn’t be enough to influence practice, he told MedPage Today.
For the original version including any supplementary images or video, visit http://www.medpagetoday.com/Cardiology/Strokes/41725
Market Report, “Vitamins and Dietary Supplements in Macedonia”, Published
It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change. Product coverage: Dietary Supplements, Paediatric Vitamins and Dietary Supplements, Tonics and Bottled Nutritive Drinks, Vitamins. Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
For the original version including any supplementary images or video, visit http://www.sbwire.com/press-releases/market-report-vitamins-and-dietary-supplements-in-macedonia-published-324955.htm